Hazelnut Component Panel
This assay is used to detect allergen specific-IgE using the ImmunoCAP® FEIA method. In vitro allergy testing is the primary testing mode for allergy diagnosis.
ProcedureThe ImmunoCAP® FEIA method uses as the solid phase a flexible, hydrophobic cellulosic polymer to which allergen has been covalently linked. The advantage of this system is that it has a very high antigen binding capacity when compared to other systems and it has minimal non-specific binding with high total IgE. Eurofins Viracor provides an optional low range calibrator at 0.1 kU/L and a 0/1 class. This test has been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
1-2 business days from receipt of specimen
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| Serum (1) | 403570P | 86008 x 4 | Yes | 1 mL |
See Scoring Guide |
|
ImmunoCAP® Quantitative Scoring Guide:
| Class | IgE (kU/L) | Comment |
| 0 | <0.10 | Negative |
| 0/1 | 0.10-0.34 | Equivocal/Borderline |
| 1 | 0.35-0.69 | Low Positive |
| 2 | 0.70-3.49 | Moderate Positive |
| 3 | 3.50-17.49 | High Positive |
| 4 | 17.50-49.99 | Very High Positive |
| 5 | 50.00-99.99 | Very High Positive |
| 6 | >99.99 | Very High Positive |
Note that Eurofins Viracor includes an extra calibrator at 0.10 kU/L and uses it to
define an optional equivocal class.
Lipemic samples may lead to rejection.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Eurofins Viracor's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
ReferencesAsero R et al. Walnut-induced anaphylaxis with cross-reactivity to hazelnut and Brazil nut. J Allergy Clin Immunol. 2004 Feb; 113(2): 358-60.
De Knop K.J. et at. Age-related sensitization profiles for hazelnut (Corylus avellana) in a birch-endemic region. Pediatr Allergy Immunol. 2011 Feb; 22(1Pt 2); e139-49.
Flinterman AE et al. Hazelnut allergy: from pollen-associated mild allergy to severe anaphylactic reactions. Curr Opin Allergy Clin Immnol. 2008 Jun; 8(3): 261-5.
Garino C et al. Isolation, cloning, and characterization of the 2S albumin: A new allergen from hazelnut. Mol. Nutr. Food Res. 2010; 54: 1257-1265.
Hansen K. S. et al. Component-resolved in vitro diagnosis of hazelnut allergy in Europe. J Allergy Clin Immunol. 2009 Apr 1; 123(5); 1134-41.
Hansen K. S. et al. Roasted hazelnuts-allergenic activity evaluated by double-blind, placebo-controlled food challenge. Allergy. 2003 Feb; 58(2); 132-8.
Lauer l et al. The non-specific lipid transfer protein, Ara h 9, is an important allergen in peanut. Clinical & Experimental Allergy, 39; 1427-1437.
Masthoff L et al. A systematic review of the effect of thermal processing on the allergenicity of tree nuts. Allergy 2013; 68: 983-993.
Masthoff L et al. Sensitization to Cor a 9 and Cor a 14 is highly specific for a sever hazelnut allergy in Dutch children and adults. J. Allergy Clin Immunol. 2013(In press).
Pastorello EA et al. Identification of hazelnut major allergens in sensitive patients with positive double-blind, placebo-controlled food challenge results. J Allergy Clin Immunol. 2002; 109(3); 563-70.
Schocker F. et al. Recombinant lipd transfer protein Cor a 8 from hazelnut: A new tool for in vitro diagnosis of potentially severe hazelnut allergy. J Allergy Clin Immunol. 2004; 113-141-7.
Verweij M et al. Young infants with atopic dermatitis can display sensitization to Cor a 9, an 11S legumin-like seed-storage protein from hazelnut (Corylus avellana). Pediatric Allergy Immnol. 2011; 22: 196-201.